4-year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation
P Osmancik, D Herman, P Neuzil, P Hala… - Journal of the American …, 2022 - jacc.org
Abstract Background The PRAGUE-17 (Left Atrial Appendage Closure vs Novel
Anticoagulation Agents in Atrial Fibrillation) trial demonstrated that left atrial appendage …
Anticoagulation Agents in Atrial Fibrillation) trial demonstrated that left atrial appendage …
Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation
P Osmancik, D Herman, P Neuzil, P Hala… - Journal of the American …, 2020 - jacc.org
Background Percutaneous left atrial appendage closure (LAAC) is noninferior to vitamin K
antagonists (VKAs) for preventing atrial fibrillation (AF)–related stroke. However, direct oral …
antagonists (VKAs) for preventing atrial fibrillation (AF)–related stroke. However, direct oral …
Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis
DR Holmes, SK Doshi, S Kar, MJ Price… - Journal of the American …, 2015 - jacc.org
Background: The risk-benefit ratio of left atrial appendage closure (LAAC) versus systemic
therapy (warfarin) for prevention of stroke, systemic embolism, and cardiovascular death in …
therapy (warfarin) for prevention of stroke, systemic embolism, and cardiovascular death in …
[HTML][HTML] Left atrial appendage closure versus oral anticoagulants in atrial fibrillation: a meta-analysis of randomized trials
MK Turagam, P Osmancik, P Neuzil… - Journal of the American …, 2020 - jacc.org
Electronic databases were searched from inception until June 23, 2020, for RCTs comparing
LAAC versus OAC in nonvalvular AF. Outcomes were all-stroke/systemic embolism (SE) …
LAAC versus OAC in nonvalvular AF. Outcomes were all-stroke/systemic embolism (SE) …
Bleeding outcomes after left atrial appendage closure compared with long-term warfarin: a pooled, patient-level analysis of the WATCHMAN randomized trial …
Objectives: The purpose of this study was to compare the relative risk of major bleeding with
left atrial appendage (LAA) closure compared with long-term warfarin therapy. Background …
left atrial appendage (LAA) closure compared with long-term warfarin therapy. Background …
Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit
SR Gangireddy, JL Halperin, V Fuster… - European heart …, 2012 - academic.oup.com
Abstract Aims The PROTECT-AF (WATCHMAN Left Atrial Appendage System for Embolic
Protection in Patients with Atrial Fibrillation) trial found left atrial appendage (LAA) closure …
Protection in Patients with Atrial Fibrillation) trial found left atrial appendage (LAA) closure …
Clinical outcomes associated with left atrial appendage occlusion versus direct oral anticoagulation in atrial fibrillation
JE Nielsen-Kudsk, K Korsholm, D Damgaard… - Cardiovascular …, 2021 - jacc.org
Objectives This study sought to investigate clinical outcomes associated with left atrial
appendage occlusion (LAAO) versus direct oral anticoagulants (DOACs) in patients with …
appendage occlusion (LAAO) versus direct oral anticoagulants (DOACs) in patients with …
5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials
VY Reddy, SK Doshi, S Kar, DN Gibson… - Journal of the American …, 2017 - jacc.org
Abstract Background: The PROTECT AF (WATCHMAN Left Atrial Appendage System for
Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that left atrial …
Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that left atrial …
Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial
VY Reddy, H Sievert, J Halperin, SK Doshi… - Jama, 2014 - jamanetwork.com
Importance While effective in preventing stroke in patients with atrial fibrillation (AF), warfarin
is limited by a narrow therapeutic profile, a need for lifelong coagulation monitoring, and …
is limited by a narrow therapeutic profile, a need for lifelong coagulation monitoring, and …
Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the …
DR Holmes, S Kar, MJ Price, B Whisenant… - Journal of the American …, 2014 - jacc.org
Abstract Background: In the PROTECT AF (Watchman Left Atrial Appendage Closure
Technology for Embolic Protection in Patients With Atrial Fibrillation) trial that evaluated …
Technology for Embolic Protection in Patients With Atrial Fibrillation) trial that evaluated …